Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1′-hydroxylation

References

• Emoto C, Iwasaki K. Enzymatic characteristics of CYP3A5 and CYP3A4: A comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 2006; 36: 219–233
   PubMed Web of Science ®Google Scholar
• Emoto C, Murase S, Iwasaki K. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 2006; 36: 671–683
   PubMed Web of Science ®Google Scholar
• Houston JB, Kenworthy KE. In vitro–in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metabolism and Disposition 2000; 28: 246–254
   PubMed Web of Science ®Google Scholar
• Jabor VA, Coelho EB, Dos Santos NA, Bonato PS, Lanchote VL. A highly sensitive LC-MS-MS assay for analysis of midazolam and its major metabolite in human plasma: Applications to drug metabolism. Journal of Chromatography B 2005; 822: 27–32
   PubMedGoogle Scholar
• Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Therapeutic Drug Monitoring 1998; 20: 243–247
   PubMed Web of Science ®Google Scholar
• Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clinical Pharmacokinetics Concepts 1994; 26: 144–160
   PubMed Web of Science ®Google Scholar
• Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology 2002; 62: 162–172
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Parker AJ, Soars M, Riley RJ. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition 2000; 28: 1327–1334
   PubMed Web of Science ®Google Scholar
• Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metabolism Reviews 2003; 35: 99–106
   PubMed Web of Science ®Google Scholar
• Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics 1985; 38: 402–408
   PubMed Web of Science ®Google Scholar
• Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42
   PubMedGoogle Scholar
• Nordt SP, Clark RF. Midazolam: A review of therapeutic uses and toxicity. Journal of Emergency Medicine 1997; 15: 357–365
   PubMedGoogle Scholar
• Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 1999; 27: 1350–1359
   PubMed Web of Science ®Google Scholar
• Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Metabolism Reviews 2002; 34: 83–448
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemical Pharmacology 1999; 57: 465–480
   PubMed Web of Science ®Google Scholar
• Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Current Drug Metabolism 2002; 3: 289–309
   PubMed Web of Science ®Google Scholar
• Soars MG, Gelboin HV, Krausz KW, Riley RJ. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. British Journal of Clinical Pharmacology 2003; 55: 175–181
   PubMed Web of Science ®Google Scholar
• Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 1995; 27: 397–417
   PubMed Web of Science ®Google Scholar
• Streetman DS, Bertino Jr,JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187–216
   PubMedGoogle Scholar
• Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. (+)-N-3-Benzyl-nirvanol and (−)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metabolism and Disposition 2002; 30: 235–239
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. Journal of Clinical Pharmacology 1996; 36: 783–791
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. Verification of the selectivity of (+)-N-3-benzylnirvanol as a CYP2C19 inhibitor. Drug Metabolism and Disposition 2003; 31: 343
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metabolism and Disposition 2004; 32: 647–660
   PubMed Web of Science ®Google Scholar
• Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochemical and Biophysical Research Communications 1999; 259: 201–205
   PubMed Web of Science ®Google Scholar
• Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition 2002; 30: 883–891
   PubMed Web of Science ®Google Scholar
• Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metabolism and Disposition 2002; 30: 1311–1319
   PubMed Web of Science ®Google Scholar